Table 4

B-CLPD: relationship between the proliferative rate of neoplastic B cells and the clinical and biologic characteristics of the disease

B-CLL, n=151
MCL, n=27
FL, n=54
Other low-grade B-CLPD*, n=51
High-grade B-CLPD,† n=21
All B-CLPD patients, n=304
% of cases% of S+G2/M cellsP% of cases% of S+G2/M cellsP% of cases% of S+G2/M cellsP% of cases% of S+G2/M cellsP% of cases% of S+G2/M cellsP% of cases% of S+G2/M cellsP
Patient characteristic                   
    Performance status                   
        ECOG 2 or less 97 0.5 ± 0.3 NS 84 3 ±4 NS 86 2.7 ±2.1 NS 87 1.5 ±2 .03 44 20 ±13 NS 11 2 ±4 <.001 
        ECOG more than 2 3 0.5 ±0.5  16 7 ±6  14 2.6 ±2.3  13 6.5 ±11  56 15 ±8  89 6 ±8  
        Adenopathies                   
        No 45 0.5 ±0.4 NS 11 4 ±6 NS 4 5.7 ±1.2 .03 71 1.5 ±1.6 NS 25 19 ±7 NS 42 1.5 ±3 NS 
        Yes 55 0.5 ±0.3  89 3 ±5  96 2.5 ±2  29 4 ±7  75 17 ±12  58 3.1 ±6  
    Infiltration of 2 or more extranodal sites                   
        No 95 0.4 ±0.4 <.01 83 2.4 ±3 NS 73 2.4 ±1.6 <.001 83 4 ±6 NS 45 12 ±7 NS 86 2 ±3.5 .001 
        Yes 5 3.5 ±6  17 1.5 ±1  26 3.3 ±3  17 10 ±13        
    B-CLL Binet stage                   
        A 75 0.4 ±0.3                 
        B 15 0.6 ±0.7 .03                
        C 10 0.7 ±0.7                 
    FL histologic grade                   
        Grade I       57 2.3 ±1.6           
        Grade II       32 2.1 ±1.5 <.05§          
        Grade III       11 5 ±2           
    Standard IPI                   
        Low (0;1) 84 0.4 ±0.3  21 3.8 ±5  45 2.2 ±2  41 1.3 ±1.3  40 21 ±13  39 5 ±8  
        Low to intermediate (2) 11 0.5 ±0.4 <.001 47 1.5 ±1.1 NS 24 2.3 ±1.4 NS 37 2 ±2.4 NS 40 11 ±8 NS 35 3.5 ±5 NS 
        High to intermediate (3) 5 2.4 ±1.2  32 6.5 ±8  24 3.3 ±2.6  18 7 ±13  13 24 ±8  22 5.7 ±8  
        High (4;5) 0   0   7 3.8 ±2  4 2.2  7 31  4 3.4 ±2  
Laboratory parameters‡                   
    WBC count less than 10×109/L 14 1.1 ±2 .03 57 5 ±6 .06 83 2.5 ±1.6 .06 24 3 ±5 .09 74 15 ±12 NS 45 4.7 ±7 <.001 
    Leukocytosis more than 10×109/L 86 0.4 ±0.4  43 2.4 ±4  17 2 ±2.5  76 1 ±1.4  26 14 ±13  55 1 ±2  
    Lymphocyte count less than 5×109/L 10 1.4 ±2.4 .06 55 4 ±4 .09 83 2.7 ±2 NS 24 3 ±6 .01 96  NS 45 5.1 ±7 <.001 
    Lymphocytosis more than 5×109/L 90 0.5 ±0.6  45 4 ±7  17 1.5 ±2  76 0.6 ±0.4  4‖   55 1 ±2.1  
    Hemoglobin                   
        Anemia less than 100 g/dL 8 0.5 ±0.4 NS 5 4 ±5 NS 4 0.4 ±0.1 .03 13 7 ±13 NS 11 30 ±1.4 .07 8 4 ±9 NS 
        More than 100 g/dL 92 0.5 ±0.9  95 0.2  96 2.5 ±2  87 2 ±2  89 16 ±10  92 2.5 ±5  
    Platelet count                   
        Thrombocytopenia less than 100×109/L 7 1.4 ±3 .01 10 7 ±8 NS 8 2.5 ±3 NS 13 8 ±12 NS 11 7 ±5 NS 9 4.3 ±7 .01 
     More than 100×109/L 93 0.5 ±0.5  90 3 ±5  92 2.5 ±2  87 2 ±2  89 18 ±11  91 2.4 ±5  
    Serum LDH                   
    Normal 94 0.5 ±0.8 .06 72 3 ±4 NS 23 2.3 ±2 NS 87 2 ±2 .01 63 17 ±11 NS 86 2 ±4.6 <.001 
    Increased more than 450 U/L 6 0.7 ±0.8  28 4 ±7  77 3.6 ±2.6  13 7 ±11  37 18 ±1o  14 5 ±7  
Patient follow-up                   
    Outcome                   
        Stable disease 64 0.4 ±0.3 NS 19 1.3 ±1 NS 14 2 ±1.6 NS 50 1.3 ±1.4 NS 0 - NS 46 0.7 ±0.9 <.001 
        Progressive disease 8 0.4 ±0.3  33 6 ±7  25 2.7 ±1.7  8 1.2 ±1  28 20 ±10  14 3.4 ±5  
    Total deaths                   
        No 90 0.5 ±0.8 NS 50 1.3 ±1.1 .007 80 2.4 ±2 NS 84 2 ±5 NS 57 15 ±12 NS 82 2 ±5 0.009 
        Yes 10 0.5 ±0.8  50 6.5 ±6.2  20 3 ±1.6  16 2 ±3  43 19 ±8  18 5 ±6  
Median survival Cutoff value Median survival, mo P Cutoff value Median survival, mo P Cutoff value Median survival, mo P Cutoff value Median survival, mo P Cutoff value; Median survival, mo P Cutoff value Median survival, mo P 
    Low proliferative rate <0.34% NR NS <1.4% NR .03 <1.8% NR NS <1% NR NS <13.7% NR NS <0.7% NR .005 
    High proliferative rate ≥0.34% NR  ≥1.4% 12  ≥1.8% NR  ≥1% 34  ≥13.7% NR  ≥0.7% 68  
B-CLL, n=151
MCL, n=27
FL, n=54
Other low-grade B-CLPD*, n=51
High-grade B-CLPD,† n=21
All B-CLPD patients, n=304
% of cases% of S+G2/M cellsP% of cases% of S+G2/M cellsP% of cases% of S+G2/M cellsP% of cases% of S+G2/M cellsP% of cases% of S+G2/M cellsP% of cases% of S+G2/M cellsP
Patient characteristic                   
    Performance status                   
        ECOG 2 or less 97 0.5 ± 0.3 NS 84 3 ±4 NS 86 2.7 ±2.1 NS 87 1.5 ±2 .03 44 20 ±13 NS 11 2 ±4 <.001 
        ECOG more than 2 3 0.5 ±0.5  16 7 ±6  14 2.6 ±2.3  13 6.5 ±11  56 15 ±8  89 6 ±8  
        Adenopathies                   
        No 45 0.5 ±0.4 NS 11 4 ±6 NS 4 5.7 ±1.2 .03 71 1.5 ±1.6 NS 25 19 ±7 NS 42 1.5 ±3 NS 
        Yes 55 0.5 ±0.3  89 3 ±5  96 2.5 ±2  29 4 ±7  75 17 ±12  58 3.1 ±6  
    Infiltration of 2 or more extranodal sites                   
        No 95 0.4 ±0.4 <.01 83 2.4 ±3 NS 73 2.4 ±1.6 <.001 83 4 ±6 NS 45 12 ±7 NS 86 2 ±3.5 .001 
        Yes 5 3.5 ±6  17 1.5 ±1  26 3.3 ±3  17 10 ±13        
    B-CLL Binet stage                   
        A 75 0.4 ±0.3                 
        B 15 0.6 ±0.7 .03                
        C 10 0.7 ±0.7                 
    FL histologic grade                   
        Grade I       57 2.3 ±1.6           
        Grade II       32 2.1 ±1.5 <.05§          
        Grade III       11 5 ±2           
    Standard IPI                   
        Low (0;1) 84 0.4 ±0.3  21 3.8 ±5  45 2.2 ±2  41 1.3 ±1.3  40 21 ±13  39 5 ±8  
        Low to intermediate (2) 11 0.5 ±0.4 <.001 47 1.5 ±1.1 NS 24 2.3 ±1.4 NS 37 2 ±2.4 NS 40 11 ±8 NS 35 3.5 ±5 NS 
        High to intermediate (3) 5 2.4 ±1.2  32 6.5 ±8  24 3.3 ±2.6  18 7 ±13  13 24 ±8  22 5.7 ±8  
        High (4;5) 0   0   7 3.8 ±2  4 2.2  7 31  4 3.4 ±2  
Laboratory parameters‡                   
    WBC count less than 10×109/L 14 1.1 ±2 .03 57 5 ±6 .06 83 2.5 ±1.6 .06 24 3 ±5 .09 74 15 ±12 NS 45 4.7 ±7 <.001 
    Leukocytosis more than 10×109/L 86 0.4 ±0.4  43 2.4 ±4  17 2 ±2.5  76 1 ±1.4  26 14 ±13  55 1 ±2  
    Lymphocyte count less than 5×109/L 10 1.4 ±2.4 .06 55 4 ±4 .09 83 2.7 ±2 NS 24 3 ±6 .01 96  NS 45 5.1 ±7 <.001 
    Lymphocytosis more than 5×109/L 90 0.5 ±0.6  45 4 ±7  17 1.5 ±2  76 0.6 ±0.4  4‖   55 1 ±2.1  
    Hemoglobin                   
        Anemia less than 100 g/dL 8 0.5 ±0.4 NS 5 4 ±5 NS 4 0.4 ±0.1 .03 13 7 ±13 NS 11 30 ±1.4 .07 8 4 ±9 NS 
        More than 100 g/dL 92 0.5 ±0.9  95 0.2  96 2.5 ±2  87 2 ±2  89 16 ±10  92 2.5 ±5  
    Platelet count                   
        Thrombocytopenia less than 100×109/L 7 1.4 ±3 .01 10 7 ±8 NS 8 2.5 ±3 NS 13 8 ±12 NS 11 7 ±5 NS 9 4.3 ±7 .01 
     More than 100×109/L 93 0.5 ±0.5  90 3 ±5  92 2.5 ±2  87 2 ±2  89 18 ±11  91 2.4 ±5  
    Serum LDH                   
    Normal 94 0.5 ±0.8 .06 72 3 ±4 NS 23 2.3 ±2 NS 87 2 ±2 .01 63 17 ±11 NS 86 2 ±4.6 <.001 
    Increased more than 450 U/L 6 0.7 ±0.8  28 4 ±7  77 3.6 ±2.6  13 7 ±11  37 18 ±1o  14 5 ±7  
Patient follow-up                   
    Outcome                   
        Stable disease 64 0.4 ±0.3 NS 19 1.3 ±1 NS 14 2 ±1.6 NS 50 1.3 ±1.4 NS 0 - NS 46 0.7 ±0.9 <.001 
        Progressive disease 8 0.4 ±0.3  33 6 ±7  25 2.7 ±1.7  8 1.2 ±1  28 20 ±10  14 3.4 ±5  
    Total deaths                   
        No 90 0.5 ±0.8 NS 50 1.3 ±1.1 .007 80 2.4 ±2 NS 84 2 ±5 NS 57 15 ±12 NS 82 2 ±5 0.009 
        Yes 10 0.5 ±0.8  50 6.5 ±6.2  20 3 ±1.6  16 2 ±3  43 19 ±8  18 5 ±6  
Median survival Cutoff value Median survival, mo P Cutoff value Median survival, mo P Cutoff value Median survival, mo P Cutoff value Median survival, mo P Cutoff value; Median survival, mo P Cutoff value Median survival, mo P 
    Low proliferative rate <0.34% NR NS <1.4% NR .03 <1.8% NR NS <1% NR NS <13.7% NR NS <0.7% NR .005 
    High proliferative rate ≥0.34% NR  ≥1.4% 12  ≥1.8% NR  ≥1% 34  ≥13.7% NR  ≥0.7% 68  

Significant differences were not found for sex, Ann Arbor stage, B symptoms, hepatomegaly, splenomegaly, bulky disease, and b-2 microglobulin serum levels.

B-CLPD indicates B-cell chronic lymphoproliferative disorders; B-CLL, B-cell chronic lymphocytic leukemia; MCL, mantle-cell lymphoma; FL, follicular lymphoma; LDH, lactic dehydrogenase; NS, no statistically significant differences found (P > .05); and NR, not reached.

‡

Results expressed as mean plus or minus 1 standard deviation.

§

P value provided corresponds to comparisons between histologic grade I and II versus grade III FL, respectively.

*

Other low-grade B-NHL: hairy cell leukemia; splenic marginal zone B-cell lymphoma; mucosa-associated lymphoid tissue lymphoma; and lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.

†

High-grade B-NHL: diffuse large B-cell lymphoma; Burkitt lymphoma; and other unclassifiable high-grade B-NHLs.

‖

Only 1 case showing 5 x 109/L or more lymphocytes.

The cutoff value used for grouping into the low and high proliferative rate categories in each diagnostic subtype corresponds to the median value of the percentage of S+G2M cells.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal